Compared with chemotherapy, nivolumab plus ipilimumab reduced the risk of disease progression or death by 79%, but further research is needed to assess overall survival.
In patients with esophageal squamous cell carcinoma, the combination of Tecentriq, tiragolumab and chemotherapy improved survival outcomes, research found.
Bristol Myers Squibb announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to investigator?s choice of chemotherapy as a first-line treatment for patients.
BEIJING and SAN FRANCISCO, Jan. 20, 2024 /PRNewswire/ Jacobio Pharmaceuticals (1167.HK), a clinical-stage oncology company focusing on undruggable targets,
Jacobio Pharmaceuticals announced data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Society of Clinical Oncology .